Loading page…

Report overview

The report describes Sun Pharma's FY17 consolidated performance, with revenue from operations of INR 315,784.4 million and total income of INR 322,015.9 million. The company expanded its specialty portfolio through products such as BromSite and Odomzo, while tildrakizumab remained filed in the US and Europe awaiting approval. It operated 42 manufacturing facilities across six continents and reported more than 30,000 employees worldwide.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2016-2017
Period: 1 April 2016 – 31 March 2017
Publication date: 26 May 2017
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

No standards or assurance data is available for this report.

ESG & Materiality

ESG data

Indicators available in this report:

Employees
Women on the board

No materiality data is available for this report.

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services